Cairn Investment Group Inc. Has $865,000 Position in Novo Nordisk A/S (NYSE:NVO)

Cairn Investment Group Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 46.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 10,050 shares of the company’s stock after selling 8,700 shares during the period. Cairn Investment Group Inc.’s holdings in Novo Nordisk A/S were worth $865,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Raymond James & Associates boosted its stake in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after buying an additional 36,223 shares during the period. Natixis Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. LPL Financial LLC lifted its stake in shares of Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the last quarter. Finally, Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on NVO shares. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Down 1.3 %

Novo Nordisk A/S stock opened at $84.05 on Thursday. The firm has a market cap of $377.17 billion, a price-to-earnings ratio of 27.20, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm has a fifty day moving average price of $94.75 and a two-hundred day moving average price of $114.02.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.